Shad ...So I'll give U the glass half full option .
AMRN / Kaiser keeps dispensing Vascepa for the MITIGATE trial and data mid year does confirm the separation in event lines seen in USA R-IT . If they use Total Event analysis they should see clear divergence in first half of 2023 .
France , Italy and Spain agree to reimburse for the R-IT indication
Germany accepts the new MITIGATE data that increases the level of evidence rating.... allowing them to start reimbursing . By this time ...mid 2023 ..Denner has control of the BOD and with the new data and reimbursement decisions ....moves quickly to sell AMRN to a Co like NVS for the remaining years of Vazkepa exclusivity .
Everyone sells at a profit and we all live happily ever after
Market Data 
Markets 
AI
